λÖãº
Ê×Ò³
>
²úÆ·ÖÐÐÄ
>
ѪС°å·´Ó¦µ°°×2(THBS2)ELISA¼ì²âÊÔ¼ÁºÐ
> ÔÚÏßÁôÑÔ
ѪС°å·´Ó¦µ°°×2(THBS2)ELISA¼ì²âÊÔ¼ÁºÐ
·µ»Ø²úÆ·ÏêÇé
ÁôÑÔÀàÐÍ
²É¹º×Éѯ
ÊÛºó×Éѯ
ÄúµÄÐÕÃû
µç»°
Email
µ¥Î»Ãû³Æ
ÁôÑÔÄÚÈÝ
ÎÒ¶ÔÄúµÄѪС°å·´Ó¦µ°°×2(THBS2)ELISA¼ì²âÊÔ¼ÁºÐ²úÆ·¸ÐÐËȤ£¬Çë·¢¾ßÌåµÄÐÅÏ¢¼°±¨¼Û£¬Ð»Ð»£¡
IPµØÖ·
3.15.145.50
ÑéÖ¤Âë
¿´²»Çå³þ£¿µã»÷ͼƬ»»Ò»ÕÅ¡£
ͬƷÅƲúÆ·£º
¦Á2¾ÞÇòµ°°×(¦Á2-MG)ELISA¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1171
)
Arylamine N-acetyltransferase 1(NAT1)ELISA¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1714
)
¿ÉÌæÄþ(Cot)ELISA¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1485
)
ϸ°ûÉ«ËØcÑõ»¯Ã¸ÑÇ»ù5B(COX5B)ELISA¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1116
)
CKB/Creatine kinase B-type ELISA¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1035
)
Ïà¹Ø²úÆ·£º
×é°·(HA)¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1173
)
5-ôÇÉ«°·(5-HT)¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
876
)
¦Ã-°±»ù¶¡Ëá(gABA)¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1065
)
¦Â-ôǶ¡Ëá(bHB)¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1112
)
»¨ÉúËÄÏ©Ëá(AA)¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
870
)